Supreme Court Denied Ramesh Balwani Appeal
The court rejected an appeal from the former Theranos executive regarding his fraud and conspiracy convictions.
Updated on Oct. 5, 2026 in Financial Crime
Live Poll
Should high-profile corporate fraud defendants be subject to stricter judicial oversight and sentencing?
The U.S. Supreme Court has rejected the appeal of former Theranos executive Ramesh Balwani. The decision leaves intact the convictions and nearly 13-year prison sentence handed down in 2022.
Why it matters
Balwani challenged his conviction by arguing that the exclusion of a 2013 recorded phone call during his trial violated his right to a fair defense. The court's refusal to hear the case effectively ends his legal efforts to overturn the verdict.
Ramesh Balwani was convicted of 10 counts of fraud and two counts of conspiracy, resulting in a prison sentence of nearly 13 years. Justice Clarence Thomas did not participate in the Supreme Court's decision to deny the hearing.
The players
Ramesh Balwani
He is the former president and chief operating officer of Theranos who was convicted on federal fraud charges.
Elizabeth Holmes
She is the disgraced founder of the defunct blood-testing company Theranos who is currently serving a prison sentence.
Clarence Thomas
He is an Associate Justice of the U.S. Supreme Court who recused himself from the vote on the appeal.
The details
Balwani, who was a key figure at the failed blood-testing startup Theranos, sought to overturn his conviction after the 9th U.S. Circuit Court of Appeals upheld the original ruling. The trial judge had previously excluded a 2013 phone call from evidence, which formed the basis of Balwani's unsuccessful appeal.
Timeline
2003: Elizabeth Holmes started Theranos in Palo Alto.
2018: Theranos collapsed.
2022: Ramesh Balwani was convicted of fraud and conspiracy.
Monday, October 5, 2026: The U.S. Supreme Court denied Balwani's appeal.
August 2027: Elizabeth Holmes is scheduled for transfer to a halfway house.
Legal Context
This case follows the established legal precedents set by the 2022 Theranos fraud convictions, which concluded a high-profile era of federal prosecution regarding Silicon Valley corporate misconduct. The denial of the appeal reinforces the judicial outcomes that have shaped modern corporate fraud sentencing.
The closure of this appeal confirms that the court-ordered restitution of $452 million to investors remains in effect. No new safety advisories or local impacts were issued in relation to the Supreme Court's procedural order.
The takeaway
The finality of this decision marks the exhaustion of appellate options for the former executive. Investors and the public should note that the financial restitution orders remain a legally binding obligation for both Balwani and Holmes.
Further reading
For additional context on the legal proceedings surrounding this case, see the Financial Crime section.
Source note: This article includes information reported by San Francisco Chronicle.
Live Poll
Should high-profile corporate fraud defendants be subject to stricter judicial oversight and sentencing?
